Jump to content

Japanese encephalitis

From Wikipedia, the free encyclopedia
(Redirected from Japanese B encephalitis)
"JEV" redirects here. For the racing driver, see Jean-Éric Vergne.
Japanese encephalitis
Other namesJapanese B encephalitis
The geographic distribution of Japanese encephalitis (dark green)
SpecialtyInfectious disease
SymptomsHeadache, fever, vomiting, confusion, seizures[1]
Usual onset5 to 15 days after infection[1]
CausesJapanese encephalitis virus (spread by mosquitoes)
Diagnostic methodBlood or cerebrospinal fluid testing[2]
PreventionJapanese encephalitis vaccine, avoiding mosquito bites[2]
TreatmentSupportive care[1]
PrognosisPermanent neurological problems occur in up to half of survivors[2]
Frequency68,000[2]
Deaths17,000[2]

Japanese encephalitis (JE) is an infection of the brain caused by the Japanese encephalitis virus (JEV).[3] While most infections result in little or no symptoms, occasional inflammation of the brain occurs.[3] In these cases, symptoms may include headache, vomiting, fever, confusion and seizures.[1] This occurs about 5 to 15 days after infection.[1]

JEV is generally spread by mosquitoes, specifically those of the Culex type.[2] Pigs and wild birds serve as a reservoir for the virus.[2] The disease occurs mostly outside of cities.[2] Diagnosis is based on blood or cerebrospinal fluid testing.[2]

Prevention is generally achieved with the Japanese encephalitis vaccine, which is both safe and effective.[2] Other measures include avoiding mosquito bites.[2] Once infected, there is no specific treatment, with care being supportive.[1] This is generally carried out in a hospital.[1] Permanent problems occur in up to half of people who recover from JE.[2]

The disease primarily occurs in East and Southeast Asia as well as the Western Pacific.[2] About 3 billion people live in areas where the disease occurs.[2] About 68,000 symptomatic cases occur a year, with about 17,000 deaths.[2] Often, cases occur in outbreaks.[2] The disease was first described in Japan in 1871.[2][4]

Signs and symptoms

[edit]

The Japanese encephalitis virus (JEV) has an incubation period of 2 to 26 days.[5] The vast majority of infections are asymptomatic: only 1 in 250 infections develop into encephalitis.[6]

Severe rigors may mark the onset of this disease in humans. Fever, headache and malaise are other non-specific symptoms of this disease which may last for a period of between 1 and 6 days. Signs which develop during the acute encephalitic stage include neck rigidity, cachexia, hemiparesis, convulsions and a raised body temperature between 38–41 °C (100.4–105.8 °F). The mortality rate of the disease is around 25% and is generally higher in children under five, the immuno-suppressed and the elderly. Transplacental spread has been noted. Neurological disorders develop in 40% of those who survive with lifelong neurological defects such as deafness, emotional lability and hemiparesis occurring in those who had central nervous system involvement.[7]

Japanese encephalitis virus enters the brain through two ways and leads to infection of neurons and encephalitis.

Increased microglial activation following Japanese encephalitis infection has been found to influence the outcome of viral pathogenesis. Microglia are the resident immune cells of the central nervous system (CNS) and have a critical role in host defense against invading microorganisms. Activated microglia secrete cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-α), which can cause toxic effects in the brain. Additionally, other soluble factors such as neurotoxins, excitatory neurotransmitters, prostaglandin, reactive oxygen, and nitrogen species are secreted by activated microglia.[8]

In a murine model of JE, it was found that in the hippocampus and the striatum, the number of activated microglia was more than anywhere else in the brain, closely followed by that in the thalamus. In the cortex, the number of activated microglia was significantly less when compared to other regions of the mouse brain. An overall induction of differential expression of proinflammatory cytokines and chemokines from different brain regions during a progressive Japanese encephalitis infection was also observed.Shukla M, Garg A, Dhole TN, Chaturvedi R (2023). "Exaggerated levels of some specific TLRs, cytokines and chemokines in Japanese encephalitis infected BV2 and neuro 2A cell lines associated with worst outcome". Virol. J.

Although the net effect of the proinflammatory mediators is to kill infectious organisms and infected cells as well as to stimulate the production of molecules that amplify the mounting response to damage, it is also evident that in a nonregenerating organ such as the brain, a dysregulated innate immune response would be deleterious. In JE the tight regulation of microglial activation appears to be disturbed, resulting in an autotoxic loop of microglial activation that possibly leads to bystander neuronal damage.[9] In animals, key signs include infertility and abortion in pigs, neurological disease in horses, and systemic signs including fever, lethargy and anorexia.[10]

Cause

[edit]

It is a disease caused by the mosquito-borne Japanese encephalitis virus (JEV).[11]

Virology

[edit]
Japanese encephalitis virus
Flavivirus structure and genome
Virus classification Edit this classification
(unranked): Virus
Realm: Riboviria
Kingdom: Orthornavirae
Phylum: Kitrinoviricota
Class: Flasuviricetes
Order: Amarillovirales
Family: Flaviviridae
Genus: Flavivirus
Species:
Japanese encephalitis virus

JEV is a virus from the family Flaviviridae, part of the Japanese encephalitis serocomplex of nine genetically and antigenically related viruses, some of which are particularly severe in horses, and four of which, including West Nile virus, are known to infect humans.[12] The enveloped virus is closely related to the West Nile virus and the St. Louis encephalitis virus. The positive sense single-stranded RNA genome is packaged in the capsid which is formed by the capsid protein. The outer envelope is formed by envelope protein and is the protective antigen. It aids in entry of the virus into the cell. The genome also encodes several nonstructural proteins (NS1, NS2a, NS2b, NS3, N4a, NS4b, NS5). NS1 is produced as a secretory form also. NS3 is a putative helicase, and NS5 is the viral polymerase. It has been noted that Japanese encephalitis infects the lumen of the endoplasmic reticulum (ER)[13][14] and rapidly accumulates substantial amounts of viral proteins.

Based on the envelope gene, there are five genotypes (I–V). The Muar strain, isolated from a patient in Malaya in 1952, is the prototype strain of genotype V. Genotype V is the earliest recognized ancestral strain.[15] The first clinical reports date from 1870, but the virus appears to have evolved in the mid-16th century. Complete genomes 372 strains of this virus have been sequenced as of 2024.[16]

Diagnosis

[edit]

Japanese encephalitis is diagnosed by commercially available tests detecting JE virus-specific IgM antibodies in serum and/or cerebrospinal fluid, for example by IgM capture ELISA.[17]

JE virus IgM antibodies are usually detectable 3 to 8 days after onset of illness and persist for 30 to 90 days, but longer persistence has been documented. Therefore, positive IgM antibodies occasionally may reflect a past infection or vaccination. Serum collected within 10 days of illness onset may not have detectable IgM, and the test should be repeated on a convalescent sample. For patients with JE virus IgM antibodies, confirmatory neutralizing antibody testing should be performed.[18] Confirmatory testing in the US is available only at the CDC and a few specialized reference laboratories. In fatal cases, nucleic acid amplification and virus culture of autopsy tissues can be useful. Viral antigen can be shown in tissues by indirect fluorescent antibody staining.[10]

Prevention

[edit]
Japanese encephalitis vaccine "ENCEVAC" in the Japanese language
Main article: Japanese encephalitis vaccine

Infection with Japanese encephalitis confers lifelong immunity. There are currently three vaccines available: SA14-14-2, IXIARO (IC51, also marketed in Australia, New Zealand as JESPECT and India as JEEV[19]) and ChimeriVax-JE (marketed as IMOJEV).[20] All current vaccines are based on the genotype III virus.[citation needed]

A formalin-inactivated mouse-brain-derived vaccine was first produced in Japan in the 1930s and was validated for use in Taiwan in the 1960s and in Thailand in the 1980s. The widespread use of vaccine and urbanization has led to control of the disease in Japan and Singapore. The high cost of this vaccine, which is grown in live mice, means that poorer countries have not been able to afford to give it as part of a routine immunization program.[11]

The most common adverse effects are redness and pain at the injection site. Uncommonly, an urticarial reaction can develop about four days after injection. Vaccines produced from mouse brain have a risk of autoimmune neurological complications of around 1 per million vaccinations.[21] However where the vaccine is not produced in mouse brains but in vitro using cell culture there are few adverse effects compared to placebo, the main side effects being headache and myalgia.[22]

The neutralizing antibody persists in the circulation for at least two to three years, and perhaps longer.[23][24] The total duration of protection is unknown, but because there is no firm evidence for protection beyond three years, boosters are recommended every 11 months for people who remain at risk.[25] Some data are available regarding the interchangeability of other JE vaccines and IXIARO.[26]

Treatment

[edit]

There is no specific treatment for Japanese encephalitis and treatment is supportive,[27] with assistance given for feeding, breathing or seizure control as required. Raised intracranial pressure may be managed with mannitol.[28] There is no transmission from person to person and therefore patients do not need to be isolated.[citation needed]

A breakthrough in the field of Japanese encephalitis therapeutics is the identification of macrophage receptor involvement in the disease severity. A recent report of an Indian group demonstrates the involvement of monocyte and macrophage receptor CLEC5A in severe inflammatory response in Japanese encephalitis infection of the brain. This transcriptomic study provides a hypothesis of neuroinflammation and a new lead in development of appropriate therapies for Japanese encephalitis.[29][30]

The effectiveness of intravenous immunoglobulin for the management of encephalitis is unclear due to a lack of evidence.[31] Intravenous immunoglobulin for Japanese encephalitis appeared to have no benefit.[31]

Epidemiology

[edit]
Disability-adjusted life year for Japanese encephalitis per 100,000 inhabitants in 2002
  no data
  less than 1
  1–5
  5–10
  10–15
  15–20
  20–25
  25–30
  30–35
  35–40
  40–45
  45–50
  more than 50

Japanese encephalitis (JE) is the leading cause of viral encephalitis in Asia, with up to 70,000 cases reported annually.[32] Case-fatality rates range from 0.3% to 60% and depend on the population and age. Rare outbreaks in U.S. territories in the Western Pacific have also occurred. Residents of rural areas in endemic locations are at highest risk; Japanese encephalitis does not usually occur in urban areas.[citation needed]

Countries which have had major epidemics in the past, but which have controlled the disease primarily by vaccination, include China, South Korea, Singapore, Japan, Taiwan and Thailand. Other countries that still have periodic epidemics include Vietnam, Cambodia, Myanmar, India, Nepal, and Malaysia. Japanese encephalitis has been reported in the Torres Strait Islands, and two fatal cases were reported in mainland northern Australia in 1998. There were reported cases in Kachin State, Myanmar in 2013. There were 116 deaths reported in Odisha's Malkangiri district of India in 2016.[citation needed]

In 2022, the notable increase in distribution of the virus in Australia due to climate change became a concern to health officials as the population has limited immunity to the disease and the presence of large numbers of farmed and feral pigs could act as reservoirs for the virus.[7] In February 2022, Japanese encephalitis was detected and confirmed in piggeries in Victoria, Queensland and New South Wales. On 4 March, cases were detected in South Australia. By October 2022, the outbreak in eastern mainland Australia had caused 42 symptomatic human cases of the disease, resulting in seven deaths.[33][34]

Humans, cattle, and horses are dead-end hosts as the disease manifests as fatal encephalitis. Pigs act as an amplifying host and have a very important role in the epidemiology of the disease. Infection in swine is asymptomatic, except in pregnant sows, when abortion and fetal abnormalities are common sequelae. The most important vector is Culex tritaeniorhynchus, which feeds on cattle in preference to humans. The natural hosts of the Japanese encephalitis virus are birds, not humans, and many believe the virus will therefore never be eliminated.[35] In November 2011, the Japanese encephalitis virus was reported in Culex bitaeniorhynchus in South Korea.[36]

Recently, whole genome microarray research of neurons infected with the Japanese encephalitis virus has shown that neurons play an important role in their own defense against Japanese encephalitis infection. Although this challenges the long-held belief that neurons are immunologically quiescent, an improved understanding of the proinflammatory effects responsible for immune-mediated control of viral infection and neuronal injury during Japanese encephalitis infection is an essential step for developing strategies for limiting the severity of CNS disease.[37]

A number of drugs have been investigated to either reduce viral replication or provide neuroprotection in cell lines or studies upon mice. None are currently advocated in treating human patients.

Evolution

[edit]

It is theorized that the virus may have originated from an ancestral virus in the mid-1500s in the Malay Archipelago region and evolved there into five different genotypes which spread across Asia.[44] The mean evolutionary rate has been estimated to be 4.35×10−4 (range: 3.49×10−4 to 5.30×10−4) nucleotide substitutions per site per year.[44]

References

[edit]
  1. ^ a b c d e f g "Symptoms and Treatment". CDC. August 2015. Archived from the original on 17 June 2017. Retrieved 29 October 2017.
  2. ^ a b c d e f g h i j k l m n o p q "Japanese encephalitis". World Health Organization. December 2015. Archived from the original on 13 July 2017. Retrieved 29 October 2017.
  3. ^ a b "Japanese Encephalitis". CDC. August 2015. Archived from the original on 24 May 2017. Retrieved 29 October 2017.
  4. ^ "Japanese encephalitis - Causes". 6 February 2019.
  5. ^ Moloney, Rachael M.; Kmush, Brittany; Rudolph, Kara E.; Cummings, Derek A. T.; Lessler, Justin (7 May 2014). "Incubation Periods of Mosquito-Borne Viral Infections: A Systematic Review". The American Journal of Tropical Medicine and Hygiene. 90 (5): 882–891. doi:10.4269/ajtmh.13-0403. PMC 4015582. PMID 24639305.
  6. ^ Simon, LV; Kruse, B (January 2018). "Japanese Encephalitis". Encephalitis, Japanese. StatPearls. PMID 29262148.
  7. ^ a b Davey, Melissa (8 March 2022). "What is Japanese encephalitis and why is it spreading in Australia?". The Guardian Australia. Retrieved 20 October 2022.
  8. ^ Mohapatra S, Chakraborty T, Basu A (October 2023). "Japanese Encephalitis virus infection in astrocytes modulate microglial function: Correlation with inflammation and oxidative stress". Cytokine.
  9. ^ Ghoshal, A; Das, S; Ghosh, S; Mishra, MK; Sharma, V; Koli, P; Sen, E; Basu, A. (2007). "Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis". Glia. 55 (5): 483–96. doi:10.1002/glia.20474. PMID 17203475. S2CID 13192982.
  10. ^ a b Japanese Encephalitis Virus Archived 18 July 2013 at the Wayback Machine reviewed and published by WikiVet, accessed 11 October 2011.
  11. ^ a b Solomon, T. (2006). "Control of Japanese encephalitis – within our grasp?". New England Journal of Medicine. 355 (9): 869–71. doi:10.1056/NEJMp058263. PMID 16943399.
  12. ^ Lobigs M, Diamond MS (2012). "Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex". Expert Rev Vaccines. 11 (2): 177–87. doi:10.1586/erv.11.180. PMC 3337329. PMID 22309667.
  13. ^ He B (March 2006). "Viruses, endoplasmic reticulum stress, and interferon responses". Cell Death Differ. 13 (3): 393–403. doi:10.1038/sj.cdd.4401833. PMID 16397582.
  14. ^ Su HL, Liao CL, Lin YL (May 2002). "Japanese encephalitis virus infection initiates endoplasmic reticulum stress and an unfolded protein response". J. Virol. 76 (9): 4162–71. doi:10.1128/JVI.76.9.4162-4171.2002. PMC 155064. PMID 11932381.
  15. ^ Gao, Xiaoyan; Liu, Hong; Li, Minghua; Fu, Shihong; Liang, Guodong (2015). "Insights into the evolutionary history of Japanese encephalitis virus (JEV) based on whole-genome sequences comprising the five genotypes". Virology Journal. 12: 43. doi:10.1186/s12985-015-0270-z. PMC 4369081. PMID 25884184.
  16. ^ "Japanese encephalitis virus complete genome". 2024.
  17. ^ Shrivastva A, Tripathi NK, Parida M, Dash PK, Jana AM, Lakshmana Rao PV (2008). "Comparison of a dipstick enzyme-linked immunosorbent assay with commercial assays for detection of Japanese encephalitis virus-specific IgM antibodies". J Postgrad Med. 54 (3): 181–5. doi:10.4103/0022-3859.40959. hdl:1807/52179. PMID 18626163.
  18. ^ Pham, David; Howard-Jones, Annaleise R.; Hueston, Linda; Jeoffreys, Neisha; Doggett, Stephen; Rockett, Rebecca J.; Eden, John-Sebastian; Sintchenko, Vitali; C-A. Chen, Sharon; O'Sullivan, Matthew V.; Maddocks, Susan; Dwyer, Dominic E.; Kok, Jen (October 2022). "Emergence of Japanese encephalitis in Australia: a diagnostic perspective". Pathology. 54 (6): 669–677. doi:10.1016/j.pathol.2022.07.001. PMID 35995617. S2CID 251422417.
  19. ^ "Jeev an inactivated Japanese Encephalitis vaccine launched in Hyderabad". pharmabiz.com. 15 September 2012. Archived from the original on 23 October 2012. Retrieved 11 January 2013.
  20. ^ Schiøler KL, Samuel M, Wai KL (2007). "Vaccines for preventing Japanese encephalitis". Cochrane Database Syst Rev. 2007 (3): CD004263. doi:10.1002/14651858.CD004263.pub2. PMC 6532601. PMID 17636750.
  21. ^ Jelinek T (July 2008). "Japanese encephalitis vaccine in travelers". Expert Rev Vaccines. 7 (5): 689–93. doi:10.1586/14760584.7.5.689. PMID 18564023. S2CID 34671998.
  22. ^ EMEA Approval of Vaccine
  23. ^ Gambel JM, DeFraites R, Hoke C, et al. (1995). "Japanese encephalitis vaccine: persistence of antibody up to 3 years after a three-dose primary series (letter)". J Infect Dis. 171 (4): 1074. doi:10.1093/infdis/171.4.1074. PMID 7706798.
  24. ^ Kurane I, Takashi T (2000). "Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains". Vaccine. 18 (Suppl): 33–5. doi:10.1016/S0264-410X(00)00041-4. PMID 10821971.
  25. ^ "Japanese Encephalitis Virus Vaccine (Intramuscular Route)". Mayo Clinic. 2024.
  26. ^ Grant M. Gallagher (13 January 2020). "Are Japanese Encephalitis Vaccines Interchangeable?".
  27. ^ Solomon T, Dung NM, Kneen R, Gainsborough M, Vaughn DW, Khanh VT (2000). "Japanese encephalitis". Journal of Neurology, Neurosurgery, and Psychiatry. 68 (9): 405–15. doi:10.1136/jnnp.68.4.405. PMC 1736874. PMID 10727474.
  28. ^ Japanese encephalitis~treatment at eMedicine
  29. ^ Nimesh Gupta; Vinay Lomash; P.V. Lakshmana Rao (September 2010). "Expression profile of Japanese encephalitis virus induced neuroinflammation and its implication in disease severity". Journal of Clinical Virology. 49 (1): 04–10. doi:10.1016/j.jcv.2010.06.009. PMID 20637688.
  30. ^ Nimesh Gupta; P.V. Lakshmana Rao (March 2011). "Transcriptomic profile of host response in Japanese encephalitis virus infection". Virology Journal. 8 (92): 92. doi:10.1186/1743-422X-8-92. PMC 3058095. PMID 21371334.
  31. ^ a b Iro, Mildred A.; Martin, Natalie G.; Absoud, Michael; Pollard, Andrew J. (2 October 2017). "Intravenous immunoglobulin for the treatment of childhood encephalitis". The Cochrane Database of Systematic Reviews. 2017 (10): CD011367. doi:10.1002/14651858.CD011367.pub2. ISSN 1469-493X. PMC 6485509. PMID 28967695.
  32. ^ Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, Ginsburg AS (November 2011). "Estimmated global incidence of Japanese encephalitis: a systematic review". Bull World Health Organ. 89 (10): 766–74. doi:10.2471/BLT.10.085233. PMC 3209971. PMID 22084515.
  33. ^ Australian Government Department of National pest & disease outbreaks (March 2022). "Japanese encephalitis".
  34. ^ "Japanese encephalitis virus". Australian Government Department of Health and Aged Care. Retrieved 20 October 2022.
  35. ^ Ghosh D, Basu A (September 2009). Brooker S (ed.). "Japanese encephalitis-a pathological and clinical perspective". PLOS Negl Trop Dis. 3 (9): e437. doi:10.1371/journal.pntd.0000437. PMC 2745699. PMID 19787040.
  36. ^ Kim, Heung Chul; Terry A. Klein; Ratree Takhampunya; Brian P. Evans; Sirima Mingmongkolchai; Ampornpan Kengluecha; John Grieco; Penny Masuoka; Myung-Soon Kim; Sung-Tae Chong; Jong-Koo Lee & Won-Ja Lee (2011). "Japanese Encephalitis Virus in Culicine Mosquitoes (Diptera: Culicidae) Collected at Daeseongdong, a Village in the Demilitarized Zone of the Republic of Korea". Journal of Medical Entomology. 48 (6): 1250–1256. doi:10.1603/me11091. PMID 22238887. S2CID 23321660.
  37. ^ Nimesh Gupta; S.R. Santhosh; J. Pradeep Babu; M.M. Parida; P.V. Lakshmana Rao (January 2010). "Chemokine profiling of Japanese encephalitis virus-infected mouse neuroblastoma cells by microarray and real-time RT-PCR: Implication in neuropathogenesis". Virus Research. 147 (1): 107–12. doi:10.1016/j.virusres.2009.10.018. PMC 7126115. PMID 19896511.
  38. ^ Swarup V, Ghosh J, Ghosh S, Saxena A, Basu A (September 2007). "Antiviral and anti-inflammatory effects of rosmarinic acid in an experimental murine model of Japanese encephalitis". Antimicrob. Agents Chemother. 51 (9): 3367–70. doi:10.1128/AAC.00041-07. PMC 2043228. PMID 17576830.
  39. ^ Swarup V, Ghosh J, Mishra MK, Basu A (March 2008). "Novel strategy for treatment of Japanese encephalitis using arctigenin, a plant lignan". J. Antimicrob. Chemother. 61 (3): 679–88. doi:10.1093/jac/dkm503. PMID 18230688.
  40. ^ Kazłowski B, Chiu YH, Kazłowska K, Pan CL, Wu CJ (August 2012). "Prevention of Japanese encephalitis virus infections by low-degree-polymerisation sulfated saccharides from Gracilaria sp. and Monostroma nitidum". Food Chem. 133 (3): 866–74. doi:10.1016/j.foodchem.2012.01.106.
  41. ^ Dutta K, Ghosh D, Basu A (May 2009). "Curcumin Protects Neuronal Cells from Japanese Encephalitis Virus-Mediated Cell Death and also Inhibits Infective Viral Particle Formation by Dysregulation of Ubiquitin-Proteasome System". J Neuroimmune Pharmacol. 4 (3): 328–37. doi:10.1007/s11481-009-9158-2. PMID 19434500. S2CID 24691000.
  42. ^ Mishra MK, Basu A (June 2008). "Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis". J. Neurochem. 105 (5): 1582–95. doi:10.1111/j.1471-4159.2008.05238.x. PMID 18208541. S2CID 205618838.
  43. ^ Mishra MK, Dutta K, Saheb SK, Basu A (December 2009). "Understanding the molecular mechanism of blood–brain barrier damage in an experimental model of Japanese encephalitis: correlation with minocycline administration as a therapeutic agent". Neurochem Int. 55 (8): 717–23. doi:10.1016/j.neuint.2009.07.006. PMID 19628016. S2CID 26964251.
  44. ^ a b Mohammed MA, Galbraith SE, Radford AD, Dove W, Takasaki T, Kurane I, Solomon T (July 2011). "Molecular phylogenetic and evolutionary analyses of Muar strain of Japanese encephalitis virus reveal it is the missing fifth genotype". Infect Genet Evol. 11 (5): 855–62. Bibcode:2011InfGE..11..855M. doi:10.1016/j.meegid.2011.01.020. PMID 21352956.
[edit]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Japanese_encephalitis&oldid=1251370291"